Cisplatin chemotherapy causes permanent, dose-dependent hearing loss and tinnitus.
Original statement
فقدان سمع وطنين دائم من السيسبلاتين
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Cisplatin chemotherapy causes permanent, dose-dependent hearing loss and tinnitus.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (rule page summary/narrative)
- Origin
- https://eltayebat.com/rule/chemo-radiation/
- Attribution uncertainty
- Written by archive operators; not attributed to Elawady.
- Claimed mechanism
Cochlear hair-cell damage
- Claimed health effect
Hearing loss, tinnitus
- Population concerned
Cisplatin-treated patients
- Geographic restriction by Elawady
none found
Scientific assessment
True – The statement is supported by robust evidence.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Permanent cisplatin ototoxicity; 18% severe-to-profound hearing loss.
2. What is demonstrably correct?
Each 100 mg/m2 cumulative cisplatin worsened hearing by 3.2 dB; 18% had severe-to-profound loss; 40% tinnitus (A-CHM-13). Ototoxicity is a recognised late effect (A-CHM-14).
3. What is wrong or exaggerated?
The archive's Arabic headline adds 'high rates even after a single dose', which the abstract does not show (cumulative doses were 200-800 mg/m2). The same review reports 95% 10-year relative survival for testicular cancer (A-CHM-14), which the archive does not mention.
4. What remains unclear?
Otoprotection strategies were not reviewed.
5. Which studies support it?
6. Which studies contradict it?
None on existence.
7. What applies to Germany and Europe?
Audiological follow-up after cisplatin is recommended.
8. What is known about Egypt?
No data reviewed.
9. What practical conclusion is appropriate?
Hearing checks during and after cisplatin; avoid noise and other ototoxic drugs.
Assessment details
- Rationale for certainty of evidence
Clear audiometric dose-response in a large survivor cohort, consistent with clinical reviews; the Arabic headline's 'even after a single dose' is not supported by the abstract.
- Source quality
Correctly cited.
- Regional transferability
High.
- Individual exceptions
Hypertension and noise worsen hearing.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Cisplatin, a key drug that cures most testicular cancers, can damage hearing permanently. The more cisplatin, the more hearing loss. About one in five survivors in one study had severe hearing loss. Hearing should be checked, and the benefit of cure must be weighed with the oncologist.
Studies on this claim
Studies supporting the claim (2)
-
Cisplatin chemotherapy causes dose-dependent permanent hearing loss
Frisina RD et al.. J Clin Oncol 2016 · PMID 27354478 · DOI 10.1200/JCO.2016.66.8822Cross-sectional studycited by the Tayebat archiveabstract only checked★ key studyAlmost 1 in 5 testicular-cancer survivors had severe-to-profound hearing loss; 40% had tinnitus.
Dose-dependent hearing loss
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure hearing after cisplatin.
- How was the study done?
Audiometry in survivors.
- How many people, animals or samples were studied?
488 men.
- What was actually found?
3.2 dB per 100 mg/m2.
- How large was the observed effect?
18% severe-profound loss.
- What do the results mean in everyday life?
Hearing checks after cisplatin.
- What are the study's limitations?
Cross-sectional.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That cisplatin should be avoided in curable testicular cancer.
-
Testicular cancer survivors face late effects but almost all survive
Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832Narrative reviewcited by the Tayebat archivefull text checked10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.
Ototoxicity listed
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review late effects.
- How was the study done?
Narrative review.
- What was actually found?
Multiple late effects.
- What do the results mean in everyday life?
Long-term check-ups and healthy lifestyle.
- What are the study's limitations?
Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Quantitative risks.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Audiological follow-up after cisplatin is recommended.
Egypt
No data reviewed.
What applies in my country?
General scientific assessment
True Cisplatin ototoxicity is real and dose-dependent.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.. Frisina RD et al.. J Clin Oncol 2016 · PMID 27354478 · DOI 10.1200/JCO.2016.66.8822
- Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832